Abstract
Recent data obtained in animals and in humans suggest that both MAO-A and MAO-B inhibitors present cognitive enhancing properties of possible interest in the treatment of cognitive disorders. In addition, the rational for using selegiline as a neuroprotector in Parkinson's disease may also be applicable in Alzheimer's disease in which a dramatic increase in the MAO-B activity has been reported. It seems then worthwhile to investigate the neuroprotective effect of MAOIs in humans and to assess, furthermore, the real therapeutical benefit of their cognitive enhancing properties.
Cite
CITATION STYLE
Delumeau, J. C., Bentue-Ferrer, D., Gandon, J. M., Amrein, R., Belliard, S., & Allain, H. (1994). Monoamine oxidase inhibitors, cognitive functions and neurodegenerative diseases. In Journal of Neural Transmission, Supplement (pp. 259–266). Springer-Verlag Wien. https://doi.org/10.1007/978-3-7091-9324-2_34
Register to see more suggestions
Mendeley helps you to discover research relevant for your work.
